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Abstract. There is a paucity of information regarding the epidemiology and outcome of COVID-19 from low/middle-
income countries, including fromNigeria. This single-center study described the clinical features, laboratory findings, and
predictors of in-hospitalmortality ofCOVID-19patients. Patients admittedbetweenApril 10, 2020andJune10, 2020were
included. Forty-five patients with a mean age of 43 (16) years, predominantly male (87%), presented with fever (38%),
cough (29%), or dyspnea (24%). In-hospital mortality was 16%. The independent predictors of mortality were hypoxemia
(adjusted odds ratio [aOR]: 2.5; 95% CI: 1.3–5.1) and creatinine > 1.5 mg/dL (aOR: 4.3; 95% CI: 1.9–9.8).
INTRODUCTION
Theworld is struggling with the COVID-19 pandemic, which
broke out in Wuhan, Hubei Province, of China in December
2019.1 The novel SARS-CoV-2 that causes COVID-19 has
overwhelmed the high-, middle-, and low-income countries.2
COVID-19 is the greatest challenge facing humans with more
than34.8million cases andmore thanamilliondeaths as stated
in the WHO situation report on October 5, 2020.3 The situation
report in Africa (September 29, 2020) also showed 1,465,023
COVID-19 cases and 35,750 (case fatality rate: 2.4%) deaths in
55 African countries inclusive of Nigeria.4 Similarly, the number
of cases in Nigeria has risen to 59,465 after the index case on
February 27, 2020 with 1,113 deaths (October 5, 2020).5
The amount of the literature available onCOVID-19 has also
risen in the past few months, spanning various aspects of the
disease, including the epidemiological profile, manifestations,
and outcomes.6 Studies showed the spectrum of illness from
asymptomatic disease to respiratory failure to multiple-organ
dysfunction in critically ill cases.7 In China, common clinical
manifestations found in patients with COVID-19 included fe-
ver, cough, breathlessness, vomiting, and diarrhea.8 Reports
from the United States also showed a similar spectrum of
presentation in the non-severe cases.9 Patients with COVID-
19 have abnormalities in laboratory parameters that include
leukopenia and lymphopenia. Some series reports derange-
ment in liver function tests, elevated blood urea, and serum
creatinine.10 Besides, a study also found elevated levels of
dimers and other biomarkers of acute inflammation.11 The
outcomes of asymptomatic to moderate COVID-19 are good
with most patients recovering with no sequel.12 By contrast,
mortality from severe and critical cases may be as high as
45%, especially in the presence of end-organ damage and
multiple-organ dysfunction syndrome (MODS).13 Besides,
older age categories above 65 years and underlying medical
conditions, including hypertension, diabetes, cardiovascular
disease, obesity, and chronic obstructive pulmonary disease,
were associated with poor outcomes.14
Despite the increasing available literature on COVID-19,
very few publications have emerged from Africa inclusive of
Nigeria.15,16 Besides, curtailing the COVID-19 pandemic in
middle- and low-income countries requires understanding the
clinical presentations, laboratory characteristics, and factors
associated with poor outcomes in patients with COVID-19. We
hypothesized thatpredictorsofoutcomesofCOVID-19 inNigeria
may differ from those in other countries. To test this hypothesis,
we described the epidemiology and outcomes of COVID-19 in a
single-center cohort of patients. We determined which factors
have an independent association with mortality.
MATERIALS AND METHODS
This studywas a retrospective review of cases of confirmed
COVID-19 admitted to the hospital isolation and treatment
center, FederalMedicalCenter, Katsina,Nigeria, fromApril 10,
2020 to June 10, 2020. All the cases of SARS-CoV-2 infection
were confirmed using a real-time PCR (RT-PCR) test of na-
sopharyngeal and oropharyngeal samples at the National
Reference Laboratory. We obtained ethical approval from the
state/hospital which granted a waiver for patients’ consent
(MOH/ADM/SUB/1152/1/373). The data were also anony-
mous with the absolute confidentiality of the patients.
The hospital is a tertiary health facility in the northwestern
part of Nigeria. It has a dedicated treatment center with a full
complement of staff and managed those with moderate, se-
vere, and critical cases of COVID-19.
The retrospective study included all adults aged 18 years
and older managed during the study period. We excluded
children andadolescents younger than18years.Weclassified
the patients, at admission, into asymptomatic, mild, moder-
ate, severe, and critical cases using the China guideline for
COVID-19 version 4. In brief, an asymptomatic patient was
anyone without symptoms. Mild cases included those with
complaints such as fever and cough with no evidence of
systemic illness. Moderate cases included patients with
* Address correspondence to Olayinka Rasheed Ibrahim, Department
of Pediatrics, Federal Medical Center, Murtala MohammedWay (Jibia
Bypass), P.M.B 2121, Katsina 820221, Nigeria. E-mail: ibroplus@
gmail.com
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high-grade fever, breathlessness, minimal supports, and ox-
ygen saturation greater than 92% in room air. Severe cases
were those patients with hypoxemia (oxygen saturation
< 92%), who required supplemental oxygen, and in need of
close monitoring. Critical cases included those patients who
required intensive care admissions including ventilatory sup-
port, end-organ damage, or multiple-organ dysfunction.
The patients had routine investigations which included full
blood count, liver function tests, electrolytes, urea and cre-
atinine, random blood sugar, blood culture where indicated,
and chest radiograph as part of the management protocol. All
the patients received antiviral (lopinavir/ritonavir), vitamin C,
zinc, and azithromycin. Besides, somepatients received other
medications based on their comorbid medical conditions. For
instance, those with underlying hypertension and diabetes
mellitus received antihypertensive and antidiabetic medica-
tions, respectively. Two patients received anti-tuberculosis
(TB) because we confirmed them to have TB during their
management. We managed the patients with the WHO stan-
dardprotocol for casemanagement; this comprised the useof
high-flow oxygen with a re-breathable mask for those with
hypoxemia and other supportive cares. Besides, two patients
with respiratory failure received mechanical ventilation, and a
patient with acute kidney injury had hemodialysis. All three
patients were managed as critical COVID-19 and received
intensive care unit (ICU) care. We followed national country
guidelines in thedischargeprotocol of thepatients. In brief, the
criteria for discharge during the early part of the case man-
agement were based on two consecutive negative RT-PCR
tests at least 48 hours apart. The discharge criteria were sub-
sequently revised to a single negative result and at present
basedon the absenceof fever for 3 days after at least 10 days of
the initial positive results. In addition, the absence of symptoms
and overall clinical satisfactory recovery, including normal sat-
uration in room air, were part of the current discharge criteria.
Definition of outcome. The primary outcome of interest
was hospitalization outcomes. The secondary outcomes in-
cluded the description of the epidemiologic characteristics,
clinical presentations, and laboratory findings of the COVID-
19 cases.
Data collection. Aminu Bashir, Nwawueze Efam Okonta,
and Muhammadu Sani Abubakar extracted the data from the
electronic health record into an Excel spreadsheet. Olayinka
Rasheed Ibrahim checked the data to ensure the accuracy of
the information which included the demographics, clinical
features, laboratory findings including the chest radiographic
findings, and outcomes whether discharged or death.
The data were analyzed using Microsoft Excel and Statis-
tical Package for Social Sciences (SPSS)™ for Windows
version 20.0 (IBMCorp., Armonk, NY). Themean and SDwere
used to summarize normally distributed continuous variables,
whereas themedian with interquartile range (IQR) was used to
summarize the skewed data. The discrete variables were
summarized using frequency tables and percentages. We
compared those who survived (at discharge) with those who
did not (death) using chi-square and Fisher’s exact tests as
appropriate. The continuous variables were compared using
the t-test and Mann–Whitney U test for normally distributed
and skewed data, respectively. A univariate analysis was
carried out using odds ratio with 95% CI, whereas a multi-
variate logistic regression was carried out on some variables
which included age, breathlessness, chest findings, pulse
rate, hypoxemia, diabetes, neutrophils, and serum creatinine.
We selected these variables basedon the literature andP-values
less than0.05on theunivariateanalysis.Themultivariateanalysis
was reported as an adjusted odds ratio (aOR) with 95% CI. The
level of statistically significant was a P-value less than 0.05.
RESULTS
A total of 45 patients with the diagnosis of COVID-19 were
managed during the study period at the Federal Medical
Center, Katsina, northwesternNigeria. Thehospital is a tertiary
health facility fairly well-equipped compared with most
COVID-19 treatment centers in Nigeria. Despite being limited
by bed spaces (15) for COVID-19, it has two functioning
ventilators with the capacity to carry out mechanical ventila-
tion and a dedicated hemodialysis machine for COVID-19.
Patients were young (Figure 1) and predominantly male
(Table 1). The predominant symptoms were fever (17, 37.8%)
and cough (13, 28.9%) as shown in Table 2. Also, nine patients
(20.0%) hadunderlying hypertension, and seven (15.6%)were
obese. The median (IQR) duration of symptoms before pre-
sentation was 4 (2–8.5) days. Based on the index of severity
(determined at the final diagnosis), most of the patients (21,
46.7%)were asymptomatic.Of 35patientswith completedata
for full blood count, 14.3% had leukocytosis (Table 3).
The survivors were younger with a lesser frequency of
symptoms (fever, cough, breathlessness, reduced appetite,
anosmia, diarrhea, and body weakness) as shown in Tables 1
and 2. The non-survivor had more of abnormal chest findings
and hypoxemia at presentation. Obesity and diabetesmellitus
were more frequent among non-survivors. The non-survivors
had longdurations of symptomsbefore thepresentation anda
shorter hospital stay. Non-survivors had more of abnormal
laboratory findings (Table 3).
The total in-hospital mortality was seven (15.6%), and all
were males with severe and critical COVID-19. Five died of
hypoxemic respiratory failure, and two died of MODS. Only
two of the patients with respiratory failure were mechanically
ventilated, and both died at 18 hours and 24 hours later. Of the
two patients with renal impairment, one had hemodialysis and
died later of MODS. After controlling for confounders, binary
logistic regression showed the independent variables pre-
dicted of poor outcomes (death) were hypoxemia with an aOR
of 2.541 (95% CI: 1.263–5.114) and serum creatinine level
above 1.5 mg/dL, aOR of 4.301 (95% CI: 1.88–9.845) as
shown in Table 4.
FIGURE 1. Age and gender distribution of the patients.
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DISCUSSIONS
Themean age of this cohort is slightly higher than the mean
age reported in an earlier Nigerian15 study, but lower than
values reported from cohorts in other studies.9,17 This study
also showed that about 50% of the cases were in the middle
age-group. This finding is comparable with observations from
cohorts in China.12 By contrast, most of the admitted cases in
Europe cohorts were in older age-groups. The difference in
age distribution between our study and the European14 study
may be because of different cohorts. Our cohort involved all
categories of cases compared with the European cohort that
involved critically ill patients managed at the ICU. The import
of the predominance of younger age found in this cohort
compared with the other cohorts suggests the need to prior-
itize screening in the age-group, especially if the country is to
curtail the spread of COVID-19. The male patients were more
affected in this study, which is consistent with other studies
and further affirm male gender is susceptible to SARS-CoV-2
infection.18,19Male gender’s higher risk ofCOVID-19 hasbeen
attributed to the role of X-linked in the immune response and
down-regulation of the angiotensin-converting enzyme 2
(ACE2) mRNA receptor, the receptor for SARS-CoV-2, by 17-
beta estradiol in female gender.20–23 The most common
TABLE 1
Demographic characteristics of the patients
Variable Total, n (%) Survivor, n (%) Non-survivor, n (%) P-value
Age (years)
< 30 10 (22.2%) 10 (26.3%) 0 0.022
30–49 22 (48.9%) 20 (52.6%) 2 (28.6%)
50–69 8 (17.8%) 4 (10.5%) 4 (57.1%)
> 75 5 (11.1%) 4 (10.5%) 1 (14.3%)
Mean (SD)
years
43 (16.0) 40.8 (15.9) 55.0 (10.8) 0.029
Gender
Male 39 (86.7%) 32 (84.2%) 7 (100%) 0.569
Female 6 (13.3%) 6 (15.8%) (0)
Total 45 38 (84.4) 7 (15.6)
Bold indicates P values that are statistically significant.
TABLE 2
Clinical features of the patients (at admission)
Variable Total, n (%) Survivor, n (%) Non-survivor, n (%) P-value
Symptoms
Fever 17 (37.8) 10 (26.3) 7 (100.0) < 0.001
Cough 13 (28.9) 7 (18.4) 6 (85.7) 0.001
Breathlessness 11 (24.4) 6 (15.8) 5 (71.4) 0.006
Reduced appetite 8 (17.8) 4 (10.5) 4 (57.1) 0.013
Anosmia 6 (13.3) 4 (10.5) 2 (28.6) 0.230
Vomiting 4 (8.9) 2 (5.3) 2 (28.6) 0.108
Diarrhea 6 (13.3) 3 (7.9) 3 (42.9) 0.039
Body weakness 6 (13.3) 3 (7.9) 3 (42.9) 0.039
Signs
Chest findings
Normal 34 (75.6) 34 (89.5) 0 < 0.001
Abnormal 11 (24.4) 4 (10.5) 7 (100.0)
Respiratory rate
20 and below 21 (46.7) 20 (52.6) 1 (14.3) 0.101
> 20 24 (53.3) 18 (47.4) 6 (85.7)
Pulse rate
100 and below 35 (77.8) 33 (86.8) 2 (28.6) 0.003
> 100 10 (22.2) 5 (13.2) 5 (71.4)
Systolic BP*
140 and below 32 (71.1) 29 (76.3) 3 (42.9) 0.168
> 140 13 (28.9) 9 (923.7) 4 (57.1)
Diastolic BP*
90 and below 40 (88.9) 35 (92.1) 5 (71.4) 0.166
> 90 5 (11.1) 3 (7.9) 2 (28.6)
Oxygen saturation†
< 92% 13 (28.9) 8 (15.8) 5 (100.0) < 0.001
92% and more 32 (71.1) 30 (84.2) 2
Underlying medical condition
Hypertension 9 (20.0.) 7 (18.4) 2 (28.6) 0.614
Diabetes mellitus 6 (13.3) 3 (7.9) 3 (42.9) 0.039
Obesity‡ 7 (15.6) 2 (5.3) 5 (71.4) < 0.001
Tuberculosis 2 (4.4) 1 (2.6) 1 (14.3) 0.290
Index of severity§
Asymptomatic 21 (46.7) 21 (55.3) 0 < 0.001
Mild 9 (20.0) 9 (23.7) 0
Moderate 4 (8.9) 4 (10.5) 0
Severek 11 (24.4) 4 (10.5) 7 (100)
Duration of hospitalization (days)
median (interquartile range)
10 (6.0–14.5) 11 (9.0–15.0) 2.0 (1.3–5.0) < 0.001
Total 45 38 (84.4) 7 (15.6)
BP = blood pressure.
*mmHg.
† # Oxygen saturation at presentation.
‡ # Defined as body mass index ³ 30 Kg/m2.
§ Final diagnosis at discharge.
k Inclusive of three critical cases.
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symptoms in this cohort included fever, cough, and breath-
lessness, which are similar to reports from the other parts of
the world.8,9,24 Most of our patients had normal liver function
tests. By contrast, ameta-analysis showed that someCOVID-
19 cases had elevated aspartate aminotransferase, alanine
aminotransferase, and reduced albumin.25 Althoughwe could
not make a definitive conclusion on the derangement of liver
function tests because of the relatively small sample size,
hepatic derangementmay be uncommon. Elevated creatinine
occurred in 5.7% of our cohort but less than 10% found
among Chinese cohorts18 and suggested the need to look for
renal impairment in adults with COVID-19 in our environment.
The chest radiographic findings in this study are similar to the
report of other researchers.26 The in-hospital mortality rate in
this cohort is 15.6%, which falls within the reported case fa-
tality rate range of 3.6–45% in the literature depending on the
cohort of studies.9,13,14,18,27 Our findings show in-hospital
mortality is about eight times higher than the country’s case
fatality rate of 1.9%.5 One reasonmay be that those who have
a severe form of the disease are the ones likely to present to a
tertiary health care facility like ours because mild cases or
asymptomatic cases may not present at the tertiary health
facilities.28 This finding could also suggest that the death rate
fromCOVID-19may be far higher than being reported. Hence,
there is a need to step up the various control measures put in
place for early case identification and prompt intervention.
This study showed that the non-survivors had more
symptoms with fever in all. By contrast, there were no differ-
ences in the symptoms between the survivors and non-
survivors in Wuhan, China.24 We also observed that the pulse
rate, abnormal chest findings, and hypoxemia were more
among the non-survivors. These findings are evidence of
systemic involvement, which predicts poor outcomes. The
non-survivors in this cohort had a shorter hospital stay.
Whereas studies from other cohort studies29–31 also showed
shorter hospital stays among the non-survivors, the duration
(days) before deathwas longer than that in this present cohort.
The reasons for the shorter hospital stay in the present study
than the cohorts outside Africa may be because of some
reasons; we observed the late presentation in the non-
survivors in our cohort and limited capacity to support ad-
vance care required in severe and critically COVID-19 cases.
Leukocytosis with neutrophilia was noticed to be more com-
mon among non-survivors. These findings contrast with an
earlier study from Wuhan in China, where there were more
leukopenia and lymphopenia cases.18 To support our
TABLE 3
Laboratory findings in the patients at presentation
Variable Total, n (%) Survivor, n (%) Non-survivor, n (%) P-value
White blood count (× 109/L) 35* 31 4
< 3.5 1 (2.9) 1 (3.2) 0 0.012
3.5–10 29 (82.9) 28 (90.3) 1 (25.0)
> 10 5 (14.3) 2 (6.5) 3 (75.0)
Lymphocyte (%) 35* 31 4
< 20 18 (51.4) 14 (45.2) 4 (100.0) 0.104
20–40 0 0 0
> 40 17 (48.6) 17 (44.7) 0
Neutrophils (%) 35* 31 4
< 40 13 (37.1) 13 (41.9) 0 0.012
40–60 13 (37.1) 13 (41.9) 0
> 60 9 (25.7) 5 (16.1) 4 (100.0)
Hemoglobin (g/dL) 35* 31 4
< 30 2 (5.7) 1 (3.2) 1 (25.0) –
³ 30 33 (73.3) 30 (96.8) 3 (75.0)
Platelets (× 109/L) 35* 31 4
< 100 5 (14.3) 4 (12.9) 1 (25.0) –
100–300 30 (85.7) 27 (87.1) 3 (75.0)
Total protein (g/L) 30† 29 1
< 60 1 (3.3) 1 (3.4) 0 1.000
60–80 29 (96.7) 28 (96.6) 1 (100.0)
Albumin (g/L) 30† 29 1
< 30 2 (6.7) 2 (6.9) 0 1.000
30–50 28 (93.3) 27 (93.1) 1 (100.0)
Aspartate aminotransferase (IU/L) 30† 29 1
Normal (< 45) 30 (100.0) 29 (100) 1 (100.0) –
Elevated 0 0 0
Alanine aminotransferase (IU/L) 30† 29 1
Normal (< 45) 29 (96.7) 28 (96.6) 1 (100.0) 1.000
Elevated 1 (3.3) 1 (3.4) 0
Serum creatinine (mg/dL) 35* 32 3
£ 1.5 33 (94.3) 32 (100) 1 (33.3) 0.005
> 1.5 2 (5.7) 0 2 (66.7)
Chest radiography 11‡ 7 4
Ground glass 5 (45.5) 3 (42.9) 2 (50.0) 0.448
Patch opacities 3 (27.3) 1 (14.3) 2 (50.0)
Normal 3 (27.3) 3 (42.9) 0
IU = International unit.
* Data available for 35 of 45 patients.
†Data available for 30 of 45 patients.
‡Data available for 11 of 45 patients.
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observation is the work of Wang et al.26 who also reported
leukocytosis, neutrophilia, and lymphopenia. The observation
of leukocytosis among the non-survivor in this cohort may
reflect the high prevalence of infections in Africa, with the
likelihood of early bacteremia complicating the viral disease.
After adjusting for confounders, the independent predictors
of death were hypoxemia and elevated creatinine above 1.5
mg/dL, which were similar to other reports. In Wuhan, China,
Xie et al.32 also identified hypoxemia as an independent pre-
dictor of mortality in COVID-19 patients. The pathophysiology
of hypoxemia-related death in COVID-19 patients involved
exacerbation of inflammatory cytokines and immune re-
sponse with a worsening cytokine storm which further led to
lung injury and persistent hypoxemia and ultimate poor out-
comes.33 In low- and middle-income countries, a handheld
portable pulse oximeter, which is cheap and affordable, may
help in early screening to identify patients with hypoxemia,
prompting early intervention. Elevated creatinine, which
shows renal impairment, was identified in a recent review to be
associated with an increase in mortality in COVID-19 pa-
tients.34 The pathophysiology of poor outcomes in the pres-
ence of renal impairmentmay be related to down-regulation of
ACE2 in response to increasing angiotensin II because of
acute lung injury with subsequent worsening of acute kidney
injury.35
Limitations. Although we could retrieve the case records
of all the patients managed during the period, a few had
incomplete investigations. Thus, only 35 had full blood
counts, 30 had liver function tests, and 11 had chest radio-
graphs among the patients. Besides, these are hospital-
based data that represented most cases from moderate to
severe COVID-19 who presented to our facility and may not
be an accurate reflection of the actual burden of COVID-19 in
the state.
CONCLUSION
Our study showed that hypoxemia and elevated creatinine
were independent predictors of mortality in patients with
COVID. In-hospital mortality in our study was eight times the
country’s case fatality rate. Leukocytosis with lymphopenia
and neutrophilia is the main laboratory finding, although they
did not predict mortality.
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Age (years) ³ 50 13 26.571 (2.744–257.280) 0.001 1.127 (0.605, 2.101) 0.706
< 49ref 32
Fever Yes 17 0.025 (0.001–0.469) 0.014 – –
Noref 28
Cough Yes 13 0.038 (0.004–0.364) 0.005 – –
Noref 32
Breathlessness Yes 11 0.075 (0.012–0.481) 0.006 1.267 (0.667,2.406) 0.470
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Reduced appetite Yes 8 0.088 (0.014–0.550) 0.009 – –
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Noref 39
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Abnormal 11
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Serum Cr (mg/dL) £ 1.5 33 108.333 (3.441–3,410.867) 0.005 4.301 (1.88–9.845) 0.001
> 1.5ref 2
OR = odds ratio, ref= reference value for the OR.
* At presentation.
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